



## Complete Summary

---

### GUIDELINE TITLE

Acute pharyngitis in children.

### BIBLIOGRAPHIC SOURCE(S)

Michigan Quality Improvement Consortium. Acute pharyngitis in children. Southfield (MI): Michigan Quality Improvement Consortium; 2007 Jan. 1 p.

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Michigan Quality Improvement Consortium. Acute pharyngitis in children. Southfield (MI): Michigan Quality Improvement Consortium; 2004 Apr. 1 p

## COMPLETE SUMMARY CONTENT

SCOPE  
METHODOLOGY - including Rating Scheme and Cost Analysis  
RECOMMENDATIONS  
EVIDENCE SUPPORTING THE RECOMMENDATIONS  
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
QUALIFYING STATEMENTS  
IMPLEMENTATION OF THE GUIDELINE  
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES  
IDENTIFYING INFORMATION AND AVAILABILITY  
DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

Acute pharyngitis, including group A beta hemolytic Streptococcus (GABHS) infection

### GUIDELINE CATEGORY

Diagnosis  
Evaluation  
Management  
Risk Assessment  
Treatment

## **CLINICAL SPECIALTY**

Family Practice  
Internal Medicine  
Otolaryngology  
Pediatrics

## **INTENDED USERS**

Advanced Practice Nurses  
Health Plans  
Physician Assistants  
Physicians

## **GUIDELINE OBJECTIVE(S)**

- To achieve significant, measurable improvements in the assessment, diagnosis, and treatment of acute pharyngitis through the development and implementation of common evidence-based clinical practice guidelines
- To design concise guidelines that are focused on key management components of acute pharyngitis to improve outcomes

## **TARGET POPULATION**

High-risk and not high-risk children and adolescents 2 to 18 years of age

## **INTERVENTIONS AND PRACTICES CONSIDERED**

### **Assessment/Diagnosis**

1. Assessment of past history of rheumatic fever or household contact with a history of rheumatic fever
2. Assessment of the likelihood of strep pharyngitis
3. Throat culture (TC) or Rapid Screen test

### **Management/Treatment**

1. Throat culture or Rapid Screen negative: symptomatic treatment, avoid antibiotics
2. Strep pharyngitis:
  - Penicillin VK
  - Amoxicillin
  - Benzathine penicillin G
  - Erythromycin ethyl succinate if penicillin allergic
  - Alternative treatment: cephalexin
3. Re-evaluation and referral to otolaryngologist, if necessary

## **MAJOR OUTCOMES CONSIDERED**

Not stated

## METHODOLOGY

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Searches of Electronic Databases

### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

The Michigan Quality Improvement Consortium (MQIC) project leader conducts a search of current literature in support of the guideline topic. Computer database searches are used to identify published studies and existing protocols and/or clinical practice guidelines on the selected topic. A database such as MEDLINE and two to three other databases are used.

### **NUMBER OF SOURCE DOCUMENTS**

Not stated

### **METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Weighting According to a Rating Scheme (Scheme Given)

### **RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE**

#### **Levels of Evidence for the Most Significant Recommendations**

- A. Randomized controlled trials
- B. Controlled trials, no randomization
- C. Observational studies
- D. Opinion of expert panel

### **METHODS USED TO ANALYZE THE EVIDENCE**

Review

### **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Not stated

### **METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Expert Consensus

### **DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Using the health plan guideline summaries and information obtained from the literature search, the Michigan Quality Improvement Consortium (MQIC) director

and/or project leader prepare a draft guideline for review by the MQIC Medical Directors.

The draft guideline and health plan guideline summaries are distributed to the MQIC Medical Directors for review and discussion at their next committee meeting.

The review/revision cycle may be conducted over several meetings before consensus is reached. Each version of the draft guideline is distributed to the MQIC Medical Directors, Measurement, and Implementation Committee members for review and comments. All feedback received is distributed to the entire membership.

Once the MQIC Medical Directors achieve consensus on the draft guideline, it is considered approved for external distribution to practitioners with review and comments requested.

## **RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

Not applicable

## **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

## **METHOD OF GUIDELINE VALIDATION**

External Peer Review  
Internal Peer Review

## **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

Once the Michigan Quality Improvement Consortium (MQIC) Medical Directors achieve consensus on the draft guideline, it is considered approved for external distribution to practitioners with review and comments requested.

The MQIC director also forwards the approved guideline draft to presidents of the appropriate state medical specialty societies for their input. All feedback received from external reviews is presented for discussion at the next MQIC Medical Directors Committee meeting. In addition, physicians are invited to attend the committee meeting to present their comments.

## **RECOMMENDATIONS**

### **MAJOR RECOMMENDATIONS**

The level of evidence grades (A-D) are provided for the most significant recommendations and are defined at the end of the "Major Recommendations" field.

## Assessment

Assess past history of rheumatic fever (especially carditis or valvular disease) or household contact with a history of rheumatic fever to identify high-risk patients.

Assess the likelihood of strep pharyngitis using the following items:

- Sudden onset
- Sore throat
- Fever
- Patchy discrete exudate
- Headache
- Nausea, vomiting, and abdominal pain
- Inflammation of pharynx and tonsils
- Tender, enlarged anterior cervical nodes
- Patient aged 5–15 years
- Presentation in winter or early spring
- History of exposure

## Diagnosis

### Not High-Risk Patients

*Probability of group A beta hemolytic streptococci (GABHS):* Low

*Testing:* None

*Treatment:* Symptomatic treatment only. **Avoid antibiotics.**

*Probability of GABHS:* Intermediate or High

*Testing:* Throat Culture (TC) **OR** Rapid Screen

*Treatment:* If TC is positive, use antibiotics.

If TC is negative, use symptomatic treatment only. **Avoid antibiotics.**

If treatment is started and culture result is negative, stop antibiotics.

If Rapid Screen is positive, use antibiotics.

If Rapid Screen is negative, culture<sup>1</sup> and only use antibiotics if throat culture is positive.

<sup>1</sup>Culture optional for age 16 and over

### High Risk Patients (history of rheumatic fever or household contact)

Start antibiotics immediately. If throat culture is obtained and is negative, stop antibiotics.

## Treatment

### Preferred Treatment for Strep Pharyngitis

1. Penicillin VK: 250–500 mg twice or three times daily (bid-tid) x 10 days
2. Amoxicillin: 20–40 mg/kg/day divided tid x 10 days **[A]**
3. Benzathine penicillin G intramuscularly (IM) x 1: 600,000 units for weight < 60 lbs; 1.2 million units for weight > 60 lbs

4. If allergic to penicillin: erythromycin ethyl succinate: 40 mg/kg/day two-four times daily (bid-qid) (max 1 g/day) x 10 days
5. With oral antibiotics, a full 10 day course is required

### **Alternative Treatment for Strep Pharyngitis**

6. Cephalexin 15 to 50 mg/kg/day divided bid or tid x 10 days

### **Re-Evaluate/Referral**

1. If failure to respond clinically after 48 hours of treatment, rule out peritonsillar or retropharyngeal abscess. If present, prompt otolaryngology (ENT) evaluation is recommended.
2. Assess the potential for a compliance problem.

### **Definitions:**

### **Levels of Evidence for the Most Significant Recommendation**

- A. Randomized controlled trials
- B. Controlled trials, no randomization
- C. Observational studies
- D. Opinion of expert panel

### **CLINICAL ALGORITHM(S)**

None provided

## **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

### **TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

The type of evidence is provided for the most significant recommendations (see "Major Recommendations" field).

This guideline is based on several sources including, the *ICSI Acute Pharyngitis Guideline*, Institute for Clinical Systems Improvement, 2005 ([www.icsi.org](http://www.icsi.org)).

## **BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

### **POTENTIAL BENEFITS**

Through a collaborative approach to developing and implementing common clinical practice guidelines and performance measures for assessment, diagnosis, and treatment of acute pharyngitis in children, Michigan health plans will achieve consistent delivery of evidence-based services and better health outcomes. This approach also will augment the practice environment for physicians by reducing the administrative burdens imposed by compliance with diverse health plan guidelines and associated requirements.

## POTENTIAL HARMS

Not stated

## QUALIFYING STATEMENTS

### QUALIFYING STATEMENTS

This guideline lists core management steps. Individual patient considerations and advances in medical science may supersede or modify these recommendations.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

When consensus is reached on a final version of the guideline, a statewide mailing of the approved guideline is completed. The guideline is distributed to physicians in the following medical specialties:

- Family Practice
- General Practice
- Internal Medicine
- Other Specialists for which the guideline is applicable (e.g., endocrinologists, allergists, pediatricians, cardiologists)

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better

### IOM DOMAIN

Effectiveness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Michigan Quality Improvement Consortium. Acute pharyngitis in children. Southfield (MI): Michigan Quality Improvement Consortium; 2007 Jan. 1 p.

### ADAPTATION

This guideline is based on several sources including, the *ICSI Acute Pharyngitis Guideline*, Institute for Clinical Systems Improvement, 2005 ([www.icsi.org](http://www.icsi.org)).

**DATE RELEASED**

2004 Apr (revised 2007 Jan)

**GUIDELINE DEVELOPER(S)**

Michigan Quality Improvement Consortium - Professional Association

**SOURCE(S) OF FUNDING**

Michigan Quality Improvement Consortium

**GUIDELINE COMMITTEE**

Michigan Quality Improvement Consortium Medical Director's Committee

**COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

Physician representatives from participating Michigan Quality Improvement Consortium health plans, Michigan State Medical Society, Michigan Osteopathic Association, Michigan Association of Health Plans, Michigan Department of Community Health, and Michigan Peer Review Organization

**FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST**

Not stated

**GUIDELINE STATUS**

This is the current release of the guideline.

This guideline updates a previous version: Michigan Quality Improvement Consortium. Acute pharyngitis in children. Southfield (MI): Michigan Quality Improvement Consortium; 2004 Apr. 1 p

**GUIDELINE AVAILABILITY**

Electronic copies: Available in Portable Document Format (PDF) from the [Michigan Quality Improvement Consortium Web site](#).

**AVAILABILITY OF COMPANION DOCUMENTS**

None available

**PATIENT RESOURCES**

None available

**NGC STATUS**



This NGC summary was completed by ECRI on November 28, 2005. The updated information was verified by the guideline developer on December 19, 2005. This NGC summary was updated by ECRI on October 16, 2006. The updated information was verified by the guideline developer on November 3, 2006. This NGC summary was updated by ECRI Institute on July 11, 2007. The updated information was verified by the guideline developer on July 16, 2007.

## **COPYRIGHT STATEMENT**

This NGC summary is based on the original guideline, which may be reproduced with the citation developed by the Michigan Quality Improvement Consortium.

## **DISCLAIMER**

### **NGC DISCLAIMER**

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 9/29/2008

